Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned a consensus rating of “Buy” from the ten analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $64.67.

Several equities analysts have recently weighed in on VERA shares. Guggenheim lifted their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective for the company. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday, March 4th.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at $5,993,989.22. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 21.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Huntington National Bank acquired a new stake in Vera Therapeutics in the fourth quarter valued at approximately $26,000. AlphaQuest LLC acquired a new stake in shares of Vera Therapeutics during the 4th quarter valued at $34,000. GF Fund Management CO. LTD. bought a new stake in Vera Therapeutics during the 4th quarter worth $56,000. KBC Group NV increased its holdings in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after purchasing an additional 1,387 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its position in Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock valued at $196,000 after purchasing an additional 639 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Trading Down 6.3 %

Shares of NASDAQ VERA opened at $21.31 on Friday. The company has a 50-day moving average of $29.82 and a two-hundred day moving average of $38.34. Vera Therapeutics has a 1-year low of $20.27 and a 1-year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.36 billion, a PE ratio of -8.16 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11. As a group, equities analysts expect that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.